Genmab — Februar 2020
-
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab https://clinicaltrials.gov/ct2/show/NCT04264884?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody&lupd_s=02%2F11%2F2020&draw=2&rank=1
-
-
Konklusionen fra 10:33 (thanks EL) kan godt tåle at blive vist her: "our study demonstrates that daratumumab-based therapy is a very effective treatment option for previously treated AL amyloidosis. In addition to producing deep hematologic responses, significant improvements in cardiac and renal organ responses can be observed, potentially translating into reduced morbidity and mortality."
-
Vi satte ny ATH i dag.:-)
-
Med meget tålmodige festdeltagere.
-
God morgen
-
God morgen
-
Godmorgen herfra også. OG stor tak til jer få stykker der checker ind hver morgen med det smil på læben. For mig signalerer det velkommen til et venligt og respektfuldt site. Selv logger jeg, som formentlig rigtig mange, på hver eneste morgen. Dog uden at sige godmorgen, da det ville se lidt mærkeligt med måske 50 godmorgen hilsner. Tak - og bliv endelig ved, så overvejer jeg det imens
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind